TAVR Trumps Traditional Valve Replacement

The Resilia technology from Edwards is made to resolve the problem of degenerating structural valves.

Transcatheter aortic valve replacement (TAVR) has been shown to have a lower incidence of deterioration compared to traditional surgical aortic valve replacement, however it is not without limitation, with a number of valves still experience issues up to five years after implementation. A bioprosthetic valve currently has an average lifecycle of 15 years, but with the devices increased application on younger individuals, there is a blatant need for TAVR to last significantly longer.

Accumulation of calcium is a major factor in the deterioration of valves. Edwards Lifesciences has manufactured Resilia, which were tested over an 8-month period and proven to have 72% less calcium than the controls.

The Mitris Resilia valve has received a “strong adoption” rate according to Edwards’ Chief Executive Officer Mike Mussallem. They are currently battling it out with Medtronic for the TAVR market following the development of The SAPIEN 3 Ultra RESILIA, coined “the only dry storage transcatheter heart valve on the U.S. market today” by vice president of transcatheter aortic valve replacement Larry Wood.

He continued to describe the device as one that “addresses one of the primary causes of reintervention following heart valve replacement.”

© Copyright 2010-2021 Zenopa LTD. All Rights Reserved.